Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 78 clinical trials
THrombo-Embolic Event in Onco-hematology

patients on vitamin K antagonists. (AVK), anti-platelet aggregation (AGP) and / or direct oral anticoagulant (AOD). In this study, the investigator means by hypocoagulability any situation modifying

coagulopathy
clot
sample analysis
deep vein thrombosis
venous thrombosis
  • 0 views
  • 25 Jan, 2021
  • 1 location
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown

infarct
antiplatelet agents
noac
fibrillation
stroke
  • 0 views
  • 25 Jan, 2021
  • 1 location
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

European guidelines recommend that the timing of the initiation of non-vitamin K antagonist oral anticoagulants (NOACs) for AF patients with cerebral infarction or TIA is association with stroke severity

infarct
diabetes
heart failure
coagulation factor
stroke
  • 13 views
  • 11 Feb, 2021
  • 1 location
Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International Multicentre Randomised-controlled Two-arm Assessor-blinded Trial

When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice. Direct oral anticoagulants (DOACs) are highly effective for secondary stroke prevention in these patients, but DOACs were never initiated <7 days after stroke onset in recent trials. …

dabigatran
stroke
edoxaban
deficit
atrial fibrillation
  • 370 views
  • 17 Feb, 2021
  • 108 locations
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)

This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in …

heparin therapy
anticoagulant therapy
thromboembolism
vitamin k
edoxaban
  • 0 views
  • 28 Jan, 2021
  • 170 locations
Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH) in patients with non-valvular atrial fibrillation (NVAF) poses a particular dilemma for thromboprophylaxis. Left atrial appendage occlusion (LAAO) is a non-pharmacological approach to prevent cardiac embolism in NVAF. The risk-benefit ratio of LAAO in patients with NVAF after ICH is unknown. The aim of STROKECLOSE is to …

noac
intracerebral hemorrhage
left atrial appendage closure
embolism
left atrial appendage occlusion
  • 0 views
  • 21 Jan, 2021
  • 2 locations
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.

Atrial fibrillation is the most common cardiac arrhythmia. In atrial fibrillation, there is a risk that clots can form in the heart, especially in the left atrium. If these clots come loose, there is a risk of stroke. To prevent strokes, patients with atrial fibrillation and status post ICB can …

anesthesia
noac
anticoagulants
fibrillation
stroke
  • 0 views
  • 24 Jan, 2021
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by Health Canada. No safety or efficacy data is available from direct head-to-head comparison of these two anticoagulants. Lawsuits in the United States over …

rivaroxaban
apixaban
probe
anticoagulants
venous thromboembolism
  • 285 views
  • 29 Jan, 2021
  • 21 locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

dabigatran
ticagrelor
aspirin
apixaban
anticoagulants
  • 112 views
  • 24 Feb, 2021
  • 76 locations
API-CAT STUDY for APIxaban Cancer Associated Thrombosis

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of anticoagulant therapy …

  • 8 views
  • 03 Mar, 2021
  • 120 locations